Abstract:161 Objectives: T cell infiltration of tumor lesions is a known prognostic factor in several tumor types and is used as treatment mechanism in some of these tumor types. Tumor infiltrating T cells express the high affinity interleukin-2 (IL2) receptor (CD25) on their surface. These T cells could therefore be visualized by molecular imaging with a radiolabeled IL2 for this receptor. For this purpose, [18F]FB-IL2 was designed as a PET imaging probe for T cell imaging, but strictly limited by its low target-to-background ratios and toxicity, which was resulted from direct binding of IL-2 to αβγ IL-2Rs on lung endothelial cells. Interaction of IL-2 with lung endothelial cells can be abrogated by blocking IL2 and IL-2Rα interaction. Here we developed a novel T cell imaging probe based on mutant Interleukin-2 (mIL2), which reduced binding to IL-2Rα and increased binding affinity for IL-2Rβ and may lead to higher target-to-background ratios and less toxicity in vivo than IL2. Methods: Mutant Interleukin-2 was expressed in Sf9 cells and purified by Ni-NTA, then concentrated using spin concentrators and purified with an FPLC Superdex 75 sizing column. The bioactivity of purified mIL2 was detected with the CTLL2 cells which were dependent upon IL-2 for growth. IL2/IL-2Rα interaction was detected by ELISA. Then, mIL2 was radiolabeled with 99mTc-HYNIC-GGGGK conjugated to the LPETG tag through Sortase A. The pharmacokinetic data of 99mTc-HYNIC-mIL2 was obtained by ex vivo biodistribution experiments. Finally, the tumor infiltrating T cells detecting capability of 99mTc-HYNIC-mIL2 in MC38 subcutaneous tumor-bearing mice was evaluated by in vivo NanoScan SPECT/CT imaging. Results: mIL2 showed bioactivity with CTLL2 cells whereas lower CD25 binding compared with IL2. The 99mTc-labeling procedure was done within 2 h, with a yield of 70%. The radiochemical purity was greater than 98%. As shown in figure 1, the tumor-infiltrating T cells located in the MC38 tumor margin was clearly visualized by 99mTc-HYNIC-mIL2 NanoScan SPECT/CT imaging with low background except relatively high kidney uptake at all detected time points (0.5 and 2 h p.i.). Specificity of 99mTc-HYNIC-mIL2 to T cells was demonstrated by competitive blocking of tumor uptake with excess mIL2. Biodistribution results showed that the tumor uptake of 99mTc-HYNIC-mIL2 at 0.5 and 2 h p.i. was 2.59 ± 0.37 %ID/g and 2.19 ± 0.16 %ID/g, respectively. Conclusions: 99mTc-HYNIC-mIL2 is a promising SPECT radiotracer for the noninvasive imaging of tumor infiltrating T cells, which showed high target-to-background ratios. This novel tracer possesses enormous potential for evaluating and guiding immunotherapy in clinical practice, and its further investigation is still in progress.

A 99tcm Labeled HYNIC Peptide "tracer" Libraries on Continuous Cellulose Membrane Supports

188Re-Labeled GX1 Dimer As a Novel Dual-Functional Probe Targeting TGM2 for Imaging and Antiangiogenic Therapy of Gastric Cancer

SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe 99Mtc-Hynic-h6f in Breast Cancer Mouse Models.

Investigation of SP94 Peptide As a Specific Probe for Hepatocellular Carcinoma Imaging and Therapy

Imaging and monitoring HER2 expression in breast cancer during trastuzumab therapy with a peptide probe 99m Tc-HYNIC-H10F

Application of 99mTc-Labeled WL12 Peptides as a Tumor PD-L1-Targeted SPECT Imaging Agent: Kit Formulation, Preclinical Evaluation, and Study on the Influence of Coligands

Small-Animal Spect/Ct Imaging with 99Mtc-Hynic-h10f Detects Her2 Expression in Mice Bearing Human Breast Cancers

Small-animal SPECT/CT Imaging of Cancer Xenografts and Pulmonary Fibrosis Using a 99m Tc-labeled Integrin Αvβ6-Targeting Cyclic Peptide with Improved in Vivo Stability

Synthesis and Biological Studies of 99m Tc(HYNIC–MFL)(tricine)(TPPTS) As a Novel Tumor Imaging Agent

Comparing two TAG-72 binding peptides previously identified by phage display as potential imaging agents.

Nitriles Form Mixed-Coligand Complexes with 99Mtc-Hynic-peptide

Identification of a High Affinity TAG-72 Binding Peptide by Phage Display Selection

99Mtc-Labeling and Evaluation of a HYNIC Modified Small-Molecular Inhibitor of Prostate-Specific Membrane Antigen.

Quantitative 99m Tc Labeling Kit for HYNIC-Conjugated Single Chain Antibody Fragments Targeting Malignant Mesothelioma

(99M)tc-Labeled Dimeric Octreotide Peptide: a Radiotracer with High Tumor Uptake for Single-Photon Emission Computed Tomography Imaging of Somatostatin Receptor Subtype 2-Positive Tumors.

99Mtc-Labeled Mutant Interleukin-2 As a Promising SPECT Probe for in Vivo Imaging of Tumor-Infiltrating T Cells

Improving Tumor-Targeting Capability and Pharmacokinetics of 99Mtc-Labeled Cyclic RGD Dimers with PEG4 Linkers

Technetium 99m–labeled VQ Peptide: A New Imaging Agent for the Early Detection of Tumors or Premalignancies

[99mTc]-labeling and evaluation of a new linear peptide for imaging of glioblastoma as a αvβ3-positive tumor

A Novel Integrinαvβ3-Targeted Isodgr Probe for SPECT/CT Imaging of Glioma

Synthesis and Preliminary Study of 99m Tc-Labeled HYNIC-FAPi for Imaging of Fibroblast Activation Proteins in Tumors